Recent Updates
Recently added Catalysts
VNRX Positive Sentiment

Detection of Early Stage I/II Cancer by Immunoassay of Crosslinked Plasma Cell Free Nucleosomes

Tuesday, October 14, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The poster presented at ISOBM 2025 discusses a new immunoassay method for detecting early-stage I/II cancer through crosslinked plasma cell-free nucleosomes. This innovative approach aims to enhance early diagnosis, potentially improving patient outcomes. The research involves notable contributors and aligns with ongoing advancements in cancer diagnostics.
Price reaction · baseline $9.054 (2025-10-13 close) · hit pre-market · 2 other VNRX headline(s) in the window, move may be shared
day 0 close · peak
+1.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • Presentation of innovative cancer detection method.
  • Potential for early diagnosis of Stage I/II cancer.
  • Involvement of reputable researchers in the study.

Full Press Release Details

Poster titled: Detection of Early Stage I/II Cancer by Immunoassay of Crosslinked Plasma Cell Free Nucleosomes
D. Pamart, G. Rommelaere, B. Cuvelier, M. Herzog, J. Micallef
Presented at ISOBM 2025

Related Articles

• Press Releases Data Showing the Prognostic Value of its Nu.Q® Cancer Test
• Poster & Publications Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

Data Showing the Prognostic Value of its Nu.Q® Cancer Test

Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

• Share
• Tweet
• Share on Facebook
• Share

Subscribe for Volition product updates .

Or, click here for Investor Updates and press releases .

" * " indicates required fields

Frequently Asked Questions

What was presented at ISOBM 2025?

A poster on a new immunoassay method for detecting early-stage I/II cancer.

Who are the authors of the study?

The study was authored by D. Pamart, G. Rommelaere, B. Cuvelier, M. Herzog, and J. Micallef.

What is the significance of the Nu.Q® Cancer Test?

It shows prognostic value in cancer detection, as highlighted in related articles.

What type of cancer is targeted by the new method?

The method targets early-stage I/II cancer for improved diagnosis.

ShareAdd on Google
Tags: VNRX Viatris Investor Conferences Healthcare cancer detection immunoassay plasma nucleosomes ISOBM 2025
Last updated: Oct 14, 2025

Biotech snapshot

Cash runway
$3M liquidity · $2M/mo burn
~1 mo
High dilution risk